B. Riley initiated coverage of Eton Pharmaceuticals (ETON) with a Buy rating and $21 price target The firm believes Eton is approaching a revenue inflection point in 2025, driven by Increlex and ET-400, which may result in profitability in 2025 with ensuing growing positive cash flow. Eton is a specialty pharmaceutical company in the ultra-rare pediatric endocrinology and metabolic genetics space focused on acquiring under-invested products with an indication-specific value proposition and late-stage candidates, the analyst tells investors in a research note.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals price target raised to $18 from $15 at Craig-Hallum
- Eton Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
- Eton Pharmaceuticals acquires Galzin
- Eton Pharmaceuticals announces final readout of PKU Golike clinical trial
- Eton Pharmaceuticals names Ipek Erdogan-Trinkaus as Chief Commercial Officer